Eisai will continue Phase III trials for its investigational sepsis drug eritoran with the enrolment of 2,000 patients.

The trial is a global, double-blind, placebo-controlled, randomised trial evaluating the investigational compound eritoran for the treatment of severe sepsis, a inflammatory condition that affects the entire body.

An independent data monitoring committee has evaluated the efficacy and safety data on 1,500 subjects and recommended enrolment of an additional 500 subjects.

Eritoran, discovered and developed by Eisai, is expected to block activation of toll-like receptor 4, which is part of an innate immune system that when activated plays an active role in the development of severe sepsis.